Cardiovascular actions of cannabinoids and their generation during shock

Journal of Molecular Medicine

Volumn 76, Issue 12, 1998, Pages 824-836

  Wagner, Jens A ^a,b,c,f   Varga, Károly ^f   Kunos, George ^d,e,f  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Department of Cardiology Angiology

^c G Kunos' Laboratory

^d SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^e MCGILL UNIVERSITY   (Canada)

^f VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

2 Arachidonyl glycerol; Anandamide; Blood pressure; Cannabinoid; Hypotension

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 [6 METHOXY 2 (4 METHOXYPHENYL) 3 BENZOFURANYLCARBONYL]BENZONITRILE; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; ANANDAMIDE; CALCIMYCIN; CANNABINOID; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; CLOTRIMAZOLE; DEXANABINOL; MITOGEN ACTIVATED PROTEIN KINASE; PROADIFEN; RIMONABANT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; BRADYCARDIA; CARDIOGENIC SHOCK; DRUG STRUCTURE; ENZYME INHIBITION; GENE LOCATION; HYPOTENSION; IMMUNOMODULATION; MOUSE; NONHUMAN; NORADRENALIN RELEASE; PATHOPHYSIOLOGY; RAT; RECEPTOR BINDING; RECEPTOR BLOCKING; RECEPTOR INTRINSIC ACTIVITY; REVIEW; SIGNAL TRANSDUCTION; TISSUE DISTRIBUTION; VASODILATATION;

EID: 0031773354     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001090050287     Document Type: Review

References (121)

1. Dewey WL (1986) Cannabinoid pharmacology. Pharmacol Rev 38:151-178
2. Friedmann H, Klein TW, Newton C, Daaka Y (1995) Marijuana, receptors and immunomodulation. Adv Exp Med Biol 373:103-113
3. Vollmer RR, Cavero I, Ertel RJ, Solomon TA, Buckley JP (1974) Role of the central nervous system in the hypotension and bradycardia induced by (-)-Δ9-trans-tetrahydrocannabinol. J Pharm Pharmacol 26:186-192
4. Cavero I, Solomon T, Buckley JP, Jandhyala BS (1973) Studies on the hypotensive activity of (-)-Δ9-trans-tetrahydrocannabinol in anesthetized dogs. Res Commun Chem Pathol Pharmacol 6:527-540
5. Graham JDP, Li DMF (1973) Cardiovascular and respiratory effects of cannabis in cat and rat. Br J Pharmacol 49:1-10
6. Dewey WL, Harris LS, Howes JF, Kennedy JS, Granchelli FE, Pars HG, Razdan RK (1970) Pharmacology of some marijuana constituents and two heterocyclic analogs. Nature 226:1255-1257
7. Hardman HF, Domino EF, Seevers MH (1971) General pharmacological actions of some synthetic tetrahydrocannabinol derivatives. Pharmacol Rev 23:295-315
8. Kanakis C, Pouget JM, Rosen KM (1976) The effects of Δ9-THC (cannabis) on cardiac performance with or without beta blockade. Circulation 53:703-709
9. Benowitz NL, Jones RT (1975) Cardiovascular effects of prolonged delta-9-tetrahydro-cannabinol ingestion. Clin Pharmacol Ther 18:287-297
10. Devane WA, Dysarz FA, Johnson LS, Melvin LS, Howlett AC (1988) Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34:605-613
11. Matsuda LA, Lolait SJ, Brownstein BJ, Young AC, Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561-564
12. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, De Costa BR, Rice KC (1990) Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 87:1932-1936
13. Kaminski NE, Abood ME, Kessler FK, Martin BR, Schatz AR (1992) Identification of a functionally relevant cannabinoid receptor on mouse spleen cells that is involved in cannabinoid-mediated immune modulation. Mol Pharmacol 42:736-742
14. Gerard CM, Mollereau C, Vassart G, Parmentier M (1991) Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem J 279:129-134
15. Munro S, Thomas KL, Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannahinoids. Nature 365:61-65
16. Matsuda LA (1997) Molecular aspects of cannabinoid receptors. Crit Rev Neurobiol 11:143-166
17. Stefano GB, Salzet B, Salzet M (1997) Identification and characterization of the leech CNS cannabinoid receptor: coupling to nitric oxide release. Brain Res 753:219-224
18. Caenazzo L, Hoehe MR, Hsieh W-T, Berretini WH, Bonner TI, Gershon ES (1991) HindIII identifies a two allele DNA polymorphism of the human cannabinoid receptor gene (CNR). Nucleic Acids Res 19:4798
19. Stubbs L, Chittenden L, Chakrabarti A, Onaivi E (1996) The gene encoding the central cannabinoid receptor is located in proximal mouse chromosome 4. Mamm Genome 7:165-166
20. Onaivi ES, Stubbs L, Chakrabarti A, Chittenden L, Hurst DP, Akinshola BE, Shire D, Reggio PH (1998) Murine cannabinoid receptor genetics. FASEB J 12:A194
21. Shire D, Carrilon C, Kaghad M, Calandra B, Rinaldi-Carmona M, LeFur G, Ferrara P (1995) An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. J Biol Chem 270:3726-3731
22. Rinaldi-Carmona M, Calandra B, Shire D, Bouaboula M, Oustric D, Barth F, Casellas P, Ferrara P, Le Fur G (1996) Characterization of two cloned human CB1 cannabinoid receptor isoforms. J Pharmacol Exp Ther 278:871-878
23. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946-1949
24. Vogel Z, Barg J, Levy R, Saya D, Heldman E, Mechoulam R (1993) Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase. J Neurochem 61:352-355
25. Felder CC, Briley EM, Axelrod J, Simpson JT, Mackie K, Devane WA (1993) Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned cannabinoid receptor and stimulates receptor mediated signal transduction. Proc Natl Acad Sci USA 90:7656-7660
26. Deadwyler SA, Hampson RE, Bennett BA, Edwards TA, Mu J, Pacheco MA, Ward SJ, Childers SR (1993) Cannabinoids modulate potassium currents in cultured hippocampal neurons. Receptors Channels 1:121-134
27. Mackie K, Lai Y, Westenbrock R, Mitchell R (1995) Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J Neurosci 15:6552-6561
28. Bouaboula M, Poinot-Chazel C, Bourrie B, Canat X, Calandra B, Rinaldi-Carmona M, LeFur G, Casellas P (1995) Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem J 312:637-641
29. Derkinderen P, Toutant P, Burgaya F, Le Bert M, Siciliano JC, de Franciscis V, Gelman M, Girault J-A (1996) Regulation of a neuronal form of focal adhesion kinase by anandamide. Science 273:1719-1722
30. Burstein S, Budrow J, Debatis M, Hunter SA, Subramanian A (1994) Phspholipase participation in cannabinoid-induced release of free arachidonic acid. Biochem Pharmacol 48:1253-1264
31. Shivachar AC, Martin BR, Ellis EF (1996) Anandamide- and Δ9-tetrahydrocannabinol-evoked arachidonic acid mobilization and blockade by SR141716 A. Biochem Pharmacol 51:669-676
32. Bayewitch M, Avidor-Reiss T, Levy R, Barg J, Mechoulam R, Vogel Z (1995) The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling. FEBS Lett 375:143-147
33. Facci L, Dal Toso R, Romanello S, Buriani A, Skaper SD, Leon A (1995) Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci USA 92:3376-3380
34. Di Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, Schwartz J-C, Piomelli D (1994) Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372:686-691
35. Cadas H, Gaillet S, Beltramo M, Venance L, Piomelli D (1996) Biosynthesis of an endogenous cannabinoid precursor in neurons and its control by calcium and cAMP. J Neurosci 16:3934-3942
36. Deutsch DG, Chin SA (1993) Enzymalic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem Pharmacol 46:791-796
37. Deyane WA, Axelrod J (1994) Enzymatic synthesis of anandamide, an endogenous ligand for the cannabinoid receptor, by brain membranes. Proc Natl Acad Sci USA 91:6698-6701
38. Hillard CJ, Campbell, WB (1997) Biochemistry and pharmacology of arachidonylethanolamide, a putative endogenous cannabinoid. J Lipid Res 38:2383-2398
39. Di Marzo V, Deutsch DG (1998) Biochemistry of the endogenous cannabinoid ligands. Semi n Neurosci (in press)
40. Ueda N, Kurahashi Y, Yamamoto S, Tokunaga T (1995) Partial purification and characterization of the porcine brain enzyme hydrolyzing and synthesizing anandamide. J Biol Chem 270: 23823-23827
41. Arreaza G, Devane WA, Omeir RL, Sajnani G, Kunz J, Cravatt BF, Deutsch DG (1997) The cloned rat hydrolytic enzyme responsible for the breakdown of anandamide also catalyzes its formation via the condensation of arachidonic acid and ethanolamine. Neurosci Lett 234:59-62
42. Schmid PC, Zuzarte-Augustin ML, Schmid HH (1985) Properties of rat liver N-acylethanolamine amidohydrolase. J Biol Chem 260:14145-14149
43. De Petrocellis L, Melck D, Ueda N, Maurelli S, Kurahashi Y, Yamamoto S, Marino G, Di Marzo V (1997) Novel inhibitors of brain, neuronal and basophilic anandamide amidohydrolase. Biochem Biophys Res Commun 231:82-88
44. Childers SR, Sexton T, Roy MB (1994) Effects of anandamide on cannabinoid receptors in rat brain membranes. Biochem Pharmacol 47:711-715
45. Hillard CJ, Edgemont WS, Campbell WB (1995) Characterization of ligand binding to the cannabinoid receptor of rat brain membranes using a novel method: application to anandamide. J Neurochem 64:677-683
46. Pertwee RG, Fernando SR, Griffin G, Abadji V, Makriyannis A (1994) Effect of phenylmethylsulphonylfluoride on the potency of anandamide as an inhibitor of electrically evoked contractions of two isolated tissue preparations. Eur J Phamacol 272:73-78
47. Adams IB, Ryan W, Singer M, Thomas BF, Compton DR, Razdan RK, Martin BR (1995) Evaluation of cannabinoid receptor binding and in vivo activities for anandamide analogs. J Pharmacol Exp Ther 273:1172-1181
48. Koutek B, Prestwich GD, Hoelett AC, Chin SA, Salehani D, Akhavan N, Deutsch DG (1994) Inhibitors of arachidonoyl ethanolamide hydrolysis. J Biol Chem 269:22937-22940
49. Deutsch DG, Omeir R, Arreaza G, Salehani D, Prestwich GD, Huang Z, Howlett A (1997) Methyl arachidonyl fluorophosphonate: a potent irreversible inhibitor of anandamide amidoase. Biochem Pharmacol 53:255-260
50. Edgemond WS, Greenberg MJ, McGinly PJ, Muthian S, Campbell WB, Hillard CJ (1998) Synthesis and characterization of diazomethylarachidonyl ketone: an irreversible inhibitor of N-arachidonylethanolamine amidohydrolase. J Pharmacol Exp Ther 286:184-190
51. Beltramo M, di Tomaso E, Piomelli D (1997) Inhibition of anandamide hydrolysis in rat brain tissue by (E)-6-(bromomethylene) tetrahydro-3-(1-naphthalenyl)-2H-pyran-2-one. FEBS Lett 403:263-267
52. De Petrocellis L, Melck D, Ueda N, Maurelli S, Kurahashi Y, Yamamoto S, Marino G, Di Marzo V (1997) Novel inhibitors of brain, neuronal, and basophilic anandamide amidohydrolase. Biochem Biophys Res Commun 231:82-88
53. Di Marzo V, De Petrocellis L, Sepe N, Buono A (1996) Biosynthesis of anandamide and related acylethanolamides in mouse J774 macrophages and N18 neuroblastoma cells. Biochem J 316:977-984
54. Wagner JA, Varga K, Ellis EF, Rzigalinski BA, Martin BR, Kunos G (1997) Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock. Nature 390:518-521
55. Varga K, Wagner JA, Bridged DT, Kunos G (1998) Platelet- and macrophage-derived cannabinoids are involved in endotoxin-induced hypotension. FASEB J 12:1035-1044
56. Beltramo M, Stella N, Calignano A, Lin SY, Makriyannis A, Piomelli D (1997) Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 277:1094-1097
57. Bisogno T, Maurelli S, Melck D, De Petrocellis L, Di Marzo V (1997) Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes. J Biol Chem 272: 3315-3323
58. Calignano A, La Kanu G, Beltramo M, Makriyannis A, Piomelli D (1997) Potentiation of anandamide hypotension by the transport inhibitor. AM404. Eur J Pharmacol 337:R1-R2
59. Hampson AJ, Hill WA, Zan-Phillips M, Makriyannis A, Leung E, Eglen RM, Bornheim LM (1995) Anandamide hydroxylation by brain lipoxygenase: metabolite structures and potencies at the cannabinoid receptor. Biochim Biophys Acta 1259:173-179
60. Ueda N, Yamamoto K, Yamamoto S, Tokunaga T, Shirakawa E, Shinkai H, Ogawa M, Sato T, Kudo I, Inoue K, et al (1995) Lipoxygenase-catalyzed oxygenation of arachidonyl-ethanolamide, a cannabinoid receptor agonist. Biochim Biophys Acta 1254:127-134
61. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminsky NE, Schatz AR, Gopher A, Almog S, Martin BR, Compton DR, Pertwee RG, Griffin G, Bayewitch M, Barg J, Vogel Z (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50:83-90
62. Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, Yamashita A, Waku K (1995) 2-Arachidonylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 215:89-97
63. Lee M, Yang KH, Kaminski NE (1995) Effects of putative cannabinoid receptor ligands, anandamide and 2-arachidonyl-glycerol, on immune function in B6C3F1 mouse splenocytes. J Pharmacol Exp Ther 275:529-536
64. Mechoulam R, Ben Shabut S, Hanus L, Fride E, Vogel Z, Bayewitch M, Sulcova AE (1996) Endogenous cannabinoid ligands - chemical and biological studies. J Lipid Mediat Cell Signal 14:45-49
65. Stella N, Schweitzer P, Piomelli D (1997) A second endogenous cannabinoid that modulates long-term potentiation. Nature 388:773-778
66. Bisogno T, Sepe N, Melck D, Maurelli S, De Petrocellis L, Di Marzo V (1997) Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonylglycerol in mouse neuroblastoma cells. Biochem J 322:671-677
67. Di Marzo V, Bisogno T, Sugiura T, Melck D, De Petrocellis L (1998) The novel endogenous cannabinoid 2-arachidonylglycerol is inactivated by neuronal- and basophil-like cells: connections with anandamide. Biochem J 331:15-19
68. Goparaju SK, Ueda N, Yamaguchi H, Yamamoto S (1998) Anandamide amidohydrolase reacting with 2-arachidonoylglycerol, another cannabinoid receptor ligand. FEBS Lett 422:69-73
69. Priller J, Briley EM, Mansouri J, Devane WA, Mackie K, Felder CC (1995) Mead ethanolamide, a novel eicosanoid, is an agonist for the central (CB1) and peripheral (CB2) cannabinoid receptors. Mol Pharmacol 48:288-292
70. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Neliat G, Caput D, Ferrara P, Soubrie P, Breliere JC, LeFur G (1994) SR141716 A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350:240-244
71. 1 receptor to stimulation of cAMP accumulation. J Pharmacol Exp Ther 284:291-297
72. 2 cannabinoid receptor. J Pharmacol Exp Ther 284:644-650
73. 2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther 278:989-999
74. Bouaboula M, Perrachon S, Milligan L, Canat X, Rinaldi-Carmona M, Portier M, Barth F, Calandra B, Pecceu F, Lupker J, Maffrand JP, LeFur G, Casellas P (1997) A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor I. Evidence for a new model of receptor/ligand interactions. J Biol Chem 272:22330-22339
75. 9-Tetrahydrocannabinol: effects on ventilatory control and cardiovascular dynamics. Anesthesiology 42:666-673
76. Rosenkrantz H (1983) Cannabis, marijuana and cannabinoid toxicological manifestations in man and animals. In: O'Brien K, Kalant H (eds) Cannabis and health hazards. Addiction Research Foundation, Toronto, pp 91-175
77. 9-tetrahydrocannabinol in the rat. J Pharmacol Exp Ther 196:649-656
78. 1-like cannabinoid receptors. J Pharmacol Exp Ther 281:1030-1037
79. Gallily R, Yamin A, Waksmann Y, Ovadia H, Weidenfeld J, Bar-Joseph A, Biegon A, Mechoulam R, Shohami E (1997) Protection against septic shock and suppression of tumor necrosis factor alpha and nitric oxide production by dexanabinol (HU-211), a nonpsychotropic cannabinoid. J Pharmacol Exp Ther 283:918-924
80. Vidrio H, Sanchez-Salvatori MA, Medina M (1996) Cardiovascular effects of (-)-11-OH-delta 8-tetrahydrocannabinol-dimethylheptyl in rats. J Cardiovasc Pharmacol 28:332-336
81. Zaugg HE, Kynel J (1983) New antihypertensive cannabinoids. J Med Chem 26:214-217
82. Adams MD, Earnhardt JT, Martin BR, Harris LS, Dewey WL, Razdan RK (1977) A cannabinoid with cardiovascular activity but no overt behavioral effects. Experientia 33:1204-1205
83. Smith PB, Compton DR, Welch SP, Razdan RK, Mechoulam R, Martin BR (1994) The pharmacological activity of anandamide a putative endogenous cannabinoid, in mice. J Pharmacol Exp Ther 270:219-227
84. Fride E, Mechoulam R (1993) Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur J Pharmacol 231:313-314
85. 1 cannabinoid receptor in the hypotensive action of anandamide. Eur J Pharmacol 278:279-283
86. Abadji V, Lin S, Taha G, Griffin G, Stevenson LA, Pertwee RG, Makryannis A (1994) (R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J Med Chem 37:1889-1893
87. Siqueira SW, Lapa AJ, Ribeiro do Valle J (1979) The triple effect induced by delta 9-tetrahydrocannabinol on the rat blood pressure. Eur J Pharmacol 58:351-357
88. Lake KD, Martin BR, Kunos G, Varga K (1997) Cardiovascular effects of anandamide in anesthetized and conscious normotensive and hypertensive rats. Hypertension 29:1204-1210
89. Varga K, Lake KD, Huangfu D, Guyenet PG, Kunos G (1996) Mechanism of the hypotensive action of anandamide in anesthetized rats. Hypertension 28:682-686
90. Carruba MO, Bondiolotti GP, Picotti GB, Catteruccia N, Da Prada M (1987) Effects of diethyl ether, halothane, ketamine and urethane on sympathetic activity in the rat. Eur J Pharmacol 134:15-24
91. Stein EA, Fuller SA, Edgemont WS, Campbell WB (1996) Physiological and behavioural effects of the endogenous cannabinoid, arachidonylethanolamide (anandamide). in the rat. Br J Pharmacol 119:107-114
92. 1 receptors on peripheral sympathetic nerves. Br J Pharmacol 118:2023-2028
93. 1 receptor-mediated inhibition of the neurogenic vasopressor response in the pithed rat. Naunyn Schmidebergs Arch Pharmacol 356:197-202
94. 2-like cannabinoid receptors on peripheral nerve terminals. Eur J Pharmacol 339:53-61
95. Herkenham M, Lynn AB, Johnson MR, Melvin LS, deCosta BR, Rice KC (1991) Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 11:563-583
96. Coutts AA, Pertwee RG (1997) Inhibition by cannabinoid receptor agonists of acetylcholine release from the guinea-pig myenteric plexus. Br J Pharmacol 121:1557-1566
97. 9-tetrahydrocannabinol on excitable membranes and neuromuscular transmission. Mol Pharmacol 17:344-349
98. 2+ currents in cat cerebral arteriolar smooth muscle cells. FASEB J 10:A302
99. 9-THC-dilation of cerebral arterioles is blocked by indomethacin Am J Physiol 269:H1859-H1864
100. Randall MD, Alexander SPH, Bennett T, Boyd EA, Fry JR, Gardiner SM, Kemp PA, McCulloch AI, Kendall DA (1996) An endogenous cannabinoid as an endothelium derived vasorelaxant. Biochem Biophys Res Commun 229:114-120
101. Randall MD, McCulloch AI, Kendall DA (1997) Comparative pharmacology of endothelium-derived hyperpolarizing factor and anandamide in rat isolated mesentery. Eur J Pharmacol 333 (2-3): 191-197
102. Mombouli JV, Vanhoutte PM (1997) Endothelium-derived hyperpolarizing factor(s): updating the unknown. Trends Pharmacol Sci 18:252-256
103. Plane F, Holland M, Waldron GJ, Garland CJ, Boyle JP (1997) Evidence that anandamide and EDHF act via different mechanisms in rat isolated mesenteric arteries. Br J Pharmacol 121:1509-1511
104. 1 receptor and endothelium-dependent hyperpolarization in guinea-pig carotid, rat mesenteric and porcine coronary arteries. Br J Pharmacol 123:968-974
105. 1 cannabinoid receptor. Am J Physiol 274:H375-H381
106. Randall MD, Kendall DA (1997) Involvement of a cannabinoid in endothelium-derived hyperpolarizing factor-mediated coronary vasorelaxation. Eur J Pharmacol 335:205-209
107. Deutsch DG, Goligorsky MS, Schmid PC, Krehshach RJ, Schmid HH, Das SK, Dey SK, Arreaza G, Thorup C, Stefano G, Moore LC (1997) Production and physiological actions of anandamide in the vasculature of the rat kidney. J Clin Invest 100:1538-1546
108. White R, Hiley CR (1997) A comparison of HDHF-mediated and anandamide-induced relaxations in the rat isolated mesenterie artery. Br J Pharmacol 122:1573-1584
109. Zygmunt PM, Hogestatt ED, Waldeck K, Edwards G, Kirkup AJ, Weston AH (1997) Studies on the effects of anandamide in rat hepatic artery. Br J Pharmacol 122:1679-1686
110. Adams IB, Compton DR, Martin BR (1998) Assessment of anandamide interaction with the cannabinoid brain receptor: SR141716 A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain. J Pharmacol Exp Ther 284:1209-1217
111. Wagner JA, Varga K, Kunos G (1998) Endotoxin induces cannabinoid-receptor mediated, endothelium-dependent vasodilation in rat mesenteric arteries. Hypertension (in press)
112. 1 receptor mRNA in human vascular cells: is 2-arachidonylglycerol a possible vasomodulator? Biochem Biophys Res Commun 243:838-843
113. Yao Y-M, Bahrami Sm Leichtfried Gm Redl H, Schlag G (1995) Pathogenesis of hemorrhage-induced bacteria/endotoxin translocation in rats. Ann Surg 221:398-405
114. Ruetten H, Thiemermann C, Vane JR (1996) Effects of the endothelin receptor antagonist. SB 209670, on circulatory failure and organ injury in endotoxic shock in the anesthetized rat. Br J Pharmacol 118: 198-204
115. Nathanson C, Hoffman WD, Suffredini AF, Eichacker PQ, Danner RL (1994) Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis. Ann Intern Mod 120:771-783
116. Pugin J, Ulevitch RJ, Tobias PS (1993) A critical role for monocytes and CD14 in endotoxin-induced endothelial cell activation. J Exp Mod 178:2193-2200
117. McCuskey RS, Urbaschek R, Urbaschek B (1996) The microcirculation during endotoxemia. Cardiovasc Res 32:752-763
118. Chandross KJ, Kessler JA, Cohen RI, Simburger E, Spray DC, Bieri P, Dermietzel R (1996) Altered connexin expression after peripheral nerve injury. Mol Cell Neurosci 7:501-518
119. Polacek D, Bech F, McKinsey JF, Davies PF (1997) Connexin43 gene expression in the rabbit arterial wall: effects of hypercholesteremia, balloon injury and their combination. J Vasc Res 34:19-30
120. Chakrabarti A, Onaivi ES, Chaudhuri G (1995) Cloning and sequencing of a cDNA encoding the mouse brain-type cannabinoid receptor protein. DNA Sequence 5:385-388
121. 2 peripheral cannabinoid receptor. Biochim Biophys Acta 1307:132-136